|
3Q12 |
3Q13 |
3Q14 |
3Q15 |
3Q16 |
3Q17 |
3Q18 |
3Q19 |
Create chart |
| Net sales revenues |
904,388 |
1,027,694 |
1,057,291 |
1,041,653 |
967,090 |
1,019,521 |
1,512,525 |
1,308,357 |
|
| Change in Fair Value of Biological Assets |
35,305 |
73,753 |
64,608 |
26,575 |
38,403 |
40,027 |
49,083 |
12,129 |
|
| Cost of Goods Sold |
-496,573 |
-568,063 |
-646,585 |
-634,127 |
-605,192 |
-628,298 |
-836,479 |
-830,288 |
|
| Depreciation / Amortization / exhaustion |
-83,348 |
-81,263 |
-103,040 |
-99,334 |
-102,906 |
-104,069 |
-173,919 |
-111,621 |
|
| Exhaustion of biological assets |
-39,976 |
-57,039 |
-43,113 |
-34,408 |
-28,219 |
-30,372 |
-123,839 |
-29,058 |
|
| Gross Profit |
319,796 |
395,082 |
329,161 |
300,359 |
269,176 |
296,809 |
427,371 |
349,519 |
|
| Selling Expenses |
-100,148 |
-116,933 |
-142,128 |
-153,869 |
-150,441 |
-165,861 |
-193,802 |
-184,497 |
|
| General and Administrative Expenses |
-27,544 |
-31,387 |
-35,149 |
-40,339 |
-33,739 |
-36,257 |
-48,676 |
-56,169 |
|
| Management Compensation |
-3,263 |
-3,985 |
-4,306 |
-3,366 |
-3,476 |
-3,881 |
-4,152 |
-4,211 |
|
| Other Operating Compensation |
3,048 |
4,470 |
1,109 |
-8,743 |
32,495 |
59,809 |
412,434 |
-11,549 |
|
| Equity income from subsidiaries |
-512 |
130 |
- |
0 |
0 |
0 |
0 |
0 |
|
| Operating Profit before Financial Income and Equity |
191,377 |
247,377 |
148,687 |
94,042 |
114,015 |
150,619 |
593,175 |
93,093 |
|
| Financial Income |
20,246 |
23,409 |
38,309 |
69,957 |
49,897 |
49,163 |
47,097 |
41,096 |
|
| Financial Expenses |
-51,953 |
-53,821 |
-82,398 |
-126,746 |
-122,537 |
-79,073 |
-74,579 |
-97,828 |
|
| Income Before Income Tax and Social Contribution |
159,670 |
216,965 |
104,598 |
37,253 |
41,375 |
120,709 |
565,693 |
36,361 |
|
| Income and social contribution taxes - current |
-21,151 |
-27,291 |
-10,304 |
-6,618 |
-10,922 |
-25,617 |
-211,627 |
-21,288 |
|
| Income Tax and Social Contribution - Deferred |
-11,416 |
-23,533 |
-10,766 |
-123 |
-598 |
-11,948 |
22,282 |
12,642 |
|
| Effect profit from discontinued operation |
-1,440 |
4,059 |
null |
null |
null |
0 |
0 |
0 |
|
| Net Income |
125,663 |
170,200 |
83,528 |
30,512 |
29,855 |
83,144 |
376,348 |
27,715 |
|
| Recurring Net Income |
122,901 |
166,141 |
83,528 |
38,771 |
9,404 |
52,242 |
61,566 |
30,472 |
|
| Recurring EBITDA |
274,642 |
310,438 |
237,331 |
226,779 |
185,908 |
204,872 |
209,566 |
237,913 |
|
| EBITDA Margin |
30.4 % |
30.2 % |
22.4 % |
21.8 % |
19.2 % |
20.1 % |
16.4 % |
18.2 % |
|
* Because of the date of the merger between Duratex and Satipel, 31.08.09, include data only from the "old" Duratex
**from 1Q 12 the data does not include discontinued operation, Deca Piazza
